Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Guanabenz for Multiple Sclerosis
NCT02423083Phase 1Terminated
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Apr 2015
- Primary completion
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of guanabenz in multiple sclerosis (MS), sponsored by National Institute of Neurological Disorders and Stroke. Primary endpoint: Maximum Tolerated Dose at 3.5 months. Started Apr 2015; status: terminated.
02
Drugs
guanabenz
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02423083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02423083.